Ever Supreme Bio Technology Co. Ltd. announced Phase IIa IND for UMSC01 in patients with Acute Myocardial Infarction was granted permission by Taiwan FDA. New drug name or code: Allogeneic umbilical cord mesenchymal stem cells(UMSC01).

Indication: For the treatment of Acute Myocardial Infarction. Planned development stages: Phase IIa IND/Phase IIb IND/Phase III IND/New Drug Application (NDA). Current development stage: (1) Application submission/approval/disapproval/each of clinical trials (include interim analysis): Approval of phase IIa IND application of UMSC01 for the treatment of patients with Acute Myocardial Infarction by Taiwan FDA.

Upcoming development plan: (1) Estimated date of completion: Depends on the progress of clinical trial. (2) Estimated responsibilities: Authorization fees, research and development costs and administrative fees. Market situation: According to Global data, the number of people suffering from acute myocardial infarction worldwide is expected to reach 30.62 million, with a compound annual growth rate (CAGR) of 2.03% from 2015 to 2025, showing that the myocardial Infarction treatment market demand continues to grow up.